ThyroSafe

This page contains recent news articles, when available, and an overview of ThyroSafe but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Nuclear fear ad criticized  -  Feb 12, 2006
There are two other FDA-approved versions of the drug, ThyroSafe and ThyroShield, according to the FDA website. ''This has become one of our best markets," ... Boston Globe

Miami Herald, The : Q & A  -  Mar 1, 2008
...only those approved by the Food and Drug Administration can legally be marketed in the US Currently, Iosat, ThyroSafe and ThyroShield have FDA approval; ... $2.95 - Miami Herald - NewsBank

First-Time Generic Approvals: Terazol 7, DDAVP Nasal Spray, Biaxin...  -  Feb 18, 2005
It is considered to be equivalent to the brand-name 65-mg tablet (ThyroSafe, made by Recip AB, Sweden, for Recip US, USA) when dissolved in liquid for oral ... Medscape

FDA first-time generics approvals--2005.(Special Report)(Illustration)  -  Feb 27, 2006
2.5 mg/300 mg, 5 mg/ 300 mg, 7.5 mg/300 mg and 10 mg/ 300 mg GENERIC DRUG NAME BRAND NAME JANUARY Potassium iodide oral solution Thyrosafe tablets USP, ... Free with registration - Chain Drug Review - AccessMyLibrary.com

FDA pipeline.(Food and Drug Administration)(drug approvals)  -  Apr 1, 2005
Potassium iodide oral solution 65 mg/mL (equiv to Thyrosafe tablets 65 mg)--FLEMING & COMPANY * Terconazole vaginal cream 0.4% (equiv to Terazole 7 Vaginal ... Free with registration - Managed Healthcare Executive - AccessMyLibrary.com

POTASSIUM IODIDE PILLS' LIFE EXTENDED - DON'T TRASH THE …  -  Jan 31, 2007
...the 2003 distribution or people wanting to obtain fresh pills can order them directly from themanufacturers, Anbex and Thyrosafe. Go to www.anbex.com. $2.95 - The Tribune - NewsBank

Article: FDA first-time generics approvals--2005.(Special Report)( …  -  Feb 27, 2006
2.5 mg/300 mg, 5 mg/ 300 mg, 7.5 mg/300 mg and 10 mg/ 300 mg GENERIC DRUG NAMEBRAND NAME JANUARY Potassium iodide oral solution Thyrosafe tablets USP, ... Pay-Per-View - Chain Drug Review - HighBeam Research

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.